Glaukos Co. (NYSE:GKOS) Shares Bought by Sei Investments Co.

Sei Investments Co. increased its holdings in shares of Glaukos Co. (NYSE:GKOS) by 51.6% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 108,546 shares of the medical instruments supplier’s stock after purchasing an additional 36,933 shares during the period. Sei Investments Co. owned 0.22% of Glaukos worth $12,847,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in GKOS. Primecap Management Co. CA increased its position in Glaukos by 43.9% in the 2nd quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock valued at $144,483,000 after acquiring an additional 372,180 shares during the period. Norges Bank acquired a new position in shares of Glaukos in the fourth quarter valued at approximately $28,807,000. Allspring Global Investments Holdings LLC raised its stake in shares of Glaukos by 148.3% during the second quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock worth $48,805,000 after purchasing an additional 246,322 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new stake in shares of Glaukos during the fourth quarter worth $15,065,000. Finally, Iron Triangle Partners LP grew its position in Glaukos by 75.6% in the 1st quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock valued at $40,500,000 after buying an additional 184,919 shares during the last quarter. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos Stock Performance

Shares of GKOS opened at $128.30 on Friday. Glaukos Co. has a 1 year low of $59.22 and a 1 year high of $136.60. The company’s 50 day simple moving average is $125.39 and its 200 day simple moving average is $112.77. The company has a market capitalization of $6.46 billion, a price-to-earnings ratio of -44.55 and a beta of 1.03. The company has a debt-to-equity ratio of 0.19, a quick ratio of 4.67 and a current ratio of 5.48.

Glaukos (NYSE:GKOS) last released its earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) EPS for the quarter, meeting the consensus estimate of ($0.52). Glaukos had a negative return on equity of 22.51% and a negative net margin of 47.39%. The firm had revenue of $95.70 million during the quarter, compared to analyst estimates of $88.86 million. During the same period in the prior year, the firm posted ($0.55) earnings per share. The business’s quarterly revenue was up 19.0% compared to the same quarter last year. On average, sell-side analysts predict that Glaukos Co. will post -2.18 EPS for the current year.

Insider Transactions at Glaukos

In related news, COO Joseph E. Gilliam sold 2,250 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $121.39, for a total transaction of $273,127.50. Following the completion of the transaction, the chief operating officer now owns 101,845 shares of the company’s stock, valued at $12,362,964.55. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Gilbert H. Kliman sold 3,000 shares of Glaukos stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $130.67, for a total value of $392,010.00. Following the transaction, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,225,345.12. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph E. Gilliam sold 2,250 shares of the stock in a transaction that occurred on Friday, July 5th. The stock was sold at an average price of $121.39, for a total transaction of $273,127.50. Following the sale, the chief operating officer now directly owns 101,845 shares of the company’s stock, valued at approximately $12,362,964.55. The disclosure for this sale can be found here. Insiders have sold a total of 41,500 shares of company stock worth $5,099,000 in the last three months. Company insiders own 6.40% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on GKOS. Needham & Company LLC upped their price objective on shares of Glaukos from $131.00 to $137.00 and gave the stock a “buy” rating in a research report on Thursday, August 1st. Piper Sandler raised their price objective on shares of Glaukos from $110.00 to $140.00 and gave the company an “overweight” rating in a research report on Thursday, August 1st. StockNews.com cut Glaukos from a “hold” rating to a “sell” rating in a research report on Friday, August 30th. Morgan Stanley raised their price target on Glaukos from $100.00 to $120.00 and gave the company an “equal weight” rating in a report on Monday, July 15th. Finally, Truist Financial reaffirmed a “buy” rating and set a $145.00 price objective (up previously from $141.00) on shares of Glaukos in a report on Thursday, August 1st. One research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Glaukos has a consensus rating of “Moderate Buy” and a consensus price target of $129.82.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.